Author: admin

Pedagogy and Success in Education: Shoshana Leffler’s Innovative Approach

Pedagogy and Success in Education: Shoshana Leffler’s Innovative Approach

Shoshana Leffler, The Bronx, New York

Shoshana Leffler, a renowned educator and developmental geneticist, is advancing pedagogy with her groundbreaking approach to STEM education in Title 1 schools. Leveraging her extensive academic background, Shoshana is redefining how science is taught, inspiring students to think critically and creatively about the world around them. Her innovative teaching methods are transforming classrooms and preparing the next generation of problem solvers and innovators.

Shoshana’s academic journey began with an A.B. in Chemistry from Princeton University, followed by a Ph.D. in Developmental Genetics from New York University. Her doctoral research, which involved developing a mathematical model of the cerebellum to predict childhood brain cancer occurrences, reflects her commitment to using science for real-world applications. This research laid the foundation for her teaching career, where she applies her scientific knowledge to inspire and engage students in meaningful ways.

“Success, to me, is about making a meaningful impact on my students’ lives and fostering a love for learning that extends beyond the classroom,” Shoshana explains. In her current role, she focuses on integrating inquiry-based learning into high school chemistry curricula, making complex scientific concepts accessible and relevant. Her methods emphasize hands-on, experiential learning, such as environmental chemistry projects and food science experiments, which engage students and foster critical thinking.

One of the biggest challenges Shoshana has faced is addressing the diverse needs of students in Title 1 schools, where resources are often limited. To overcome this, she focuses on maximizing available resources and being creative in her approach. “By creating an inclusive and adaptable learning environment, I aim to overcome barriers and ensure that every student has the opportunity to succeed,” she says. Her efforts have led to noticeable improvements in student engagement and understanding, particularly in chemistry classes.

Shoshana’s work extends beyond the classroom. She collaborates with fellow educators to develop training programs and resources that promote inquiry-based learning across educational settings. She is also actively involved in community initiatives that emphasize education and sustainability, further extending her influence and impact. “Education isn’t just about test scores; it’s about developing curious, informed citizens who are ready to make a positive impact in their communities,” Shoshana emphasizes.

Looking ahead, Shoshana is committed to expanding her impact in STEM education by developing more resources and training programs for teachers, particularly in underserved communities. Her vision is to create an educational environment where every student has the tools and support they need to succeed in STEM and beyond. “My goal is to create a classroom where students feel safe to ask questions and make mistakes. That’s how real learning happens,” she asserts.

Through her dedication and vision, Shoshana Leffler is not only transforming the way science is taught but also inspiring a new generation of innovators and problem solvers. Her work is a testament to the power of education in shaping a brighter future.

The full interview with Shoshana Leffler can be read at Industry Elites.

Media Contact
Contact Person: Shoshana Leffler
Email: Send Email
City: The Bronx
State: New York
Country: United States
Website: shoshanaleffler.com

Dr. Mohiba Tareen of Tareen Dermatology Featured in Exclusive Interview on Inspirery

Dr. Mohiba Tareen of Tareen Dermatology Featured in Exclusive Interview on Inspirery

Tareen Dermatology, Roseville, MN, USA
Dr. Mohiba Tareen, the visionary Founder and Medical Director of Tareen Dermatology, has been featured in an exclusive interview on Inspirery, where she shares her journey, insights, and the principles that drive her successful practice.

Dr. Mohiba Tareen, the visionary Founder and Medical Director of Tareen Dermatology, has been featured in an exclusive interview on Inspirery, where she shares her journey, insights, and the principles that drive her successful practice. Dr. Tareen, a nationally recognized board-certified dermatologist, discusses her passion for blending art and science in dermatology, the challenges of scaling her practice while maintaining personalized care, and the importance of staying current with the latest advancements in the field.

In the interview, Dr. Tareen opens up about the inspiration behind her career in dermatology and how it has evolved over time. She emphasizes the unique approach at Tareen Dermatology, where patient-centered care is at the forefront, and the practice’s commitment to ongoing innovation and community outreach. Dr. Tareen also shares valuable advice for young dermatologists and highlights upcoming initiatives that will further enhance the services offered at Tareen Dermatology.

Dr. Tareen’s interview provides a deep dive into the challenges and triumphs of running a successful dermatology practice, balancing a demanding career with motherhood, and her vision for the future of Tareen Dermatology.

About Dr. Mohiba Tareen

Dr. Mohiba Tareen is a board-certified dermatologist and the Founder and Medical Director of Tareen Dermatology. She established the practice in 2011 to provide cutting-edge, compassionate care in medical, cosmetic, and surgical dermatology. A magna cum laude graduate of the University of Michigan, Dr. Tareen is recognized for her expertise in Mohs surgery for skin cancer and her contributions to advancing the field of dermatology. She is deeply committed to patient education, innovation, and giving back to the community.

To read the full interview, click here.

Media Contact
Company Name: Tareen Dermatology
Email: Send Email
City: Roseville
State: MN
Country: United States
Website: https://www.tareendermatology.com/

Digital Payment Market Recent Growth Factors, Size, Share, Top Companies, Industry Analysis, Future Development & Forecast – 2028

“PayPal (US), Fiserv (US), FIS (US), Global Payments (US), Square (US), Stripe (US), VISA (US), Mastercard (US), Worldline (France), Adyen (Netherlands), ACI Worldwide (US), Temenos (Switzerland), PayU (Netherlands), Apple (US), JPMorgan Chase (US), WEX (US), FLEETCOR (US).”
Digital Payment Market by Offering (Solutions (Payment Processor, Payment Gateway, Payment Wallet, POS Solution), Services (Professional and Managed), Transaction Type (Domestic and Cross Border), Payment Mode, Vertical & Region – Global Forecast to 2028.

The digital payment market is booming, expected to surge from $111.2 billion in 2023 to $193.7 billion by 2028, fueled by a growing online consumer base and shifting consumer payment habits. New technology players are entering the market, aiming to disrupt the industry by offering superior customer experiences. Digital currencies are poised to revolutionize the global payments landscape, offering technological innovation, instant transactions, and enhanced security. These factors are driving the rapid growth of the digital payment market.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209834053  

By Solution, the payment processors segment holds the largest market size during the forecast period.

The payment processor provides a connection between the issuer bank and the merchant bank, as well as enables merchants to receive payments. Payment processing solutions offer a secure and scalable processing platform that processes domestic, inter-regional, and international credit card transactions. The payment processor sector within the financial industry pertains to firms or entities that facilitate electronic payment transactions between merchants and consumers. These payment processors have a crucial function in guaranteeing the secure and effective movement of funds across a spectrum of transactions, encompassing online purchases, in-person transactions, mobile payments, and other forms of financial interactions.

By offering, the service segment is expected to grow with the highest CAGR during the forecast period.

The services segment has been broadly classified into professional services and managed services. The professional services segment includes consulting, implementation, and support and maintenance. Digital payment vendors offer professional and managed services to plan, design, implement, and deploy digital payment solutions. Support and maintenance services help ensure the overall development of digital payment solutions, which is expected to drive the growth of the services segment.

Asia Pacific is expected to hold the largest market size during the forecast period.

The APAC region is experiencing rapid adoption of digital payments due to favorable regulatory conditions, infrastructure enhancements, widespread smartphone use, and affordable data rates. This growth trajectory is particularly robust as governments in the region actively promote digital transformation, resulting in significant industry-wide changes. Regulatory and market shifts are replacing the marketplace. With the emergence of the new challenger bank and fintech offerings, digital payment services have led to increased customer experience and collaboration between banks and fintech institutions in the region. The rapid eCommerce adoption also contributes to the increased use of digital payment solutions.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=209834053  

Unique Features in the Digital Payment Market

One of the most significant features of the digital payment market is the ability to conduct seamless and instant transactions. Digital payment platforms enable users to transfer money, pay for goods and services, and complete financial transactions within seconds.

The digital payment market offers a diverse array of payment options, catering to different user preferences and needs. These include mobile wallets, digital currencies, peer-to-peer (P2P) payment platforms, contactless payments, and more.

Security is a critical feature of the digital payment market, with providers employing advanced technologies to protect users’ financial information. These security measures include encryption, tokenization, biometric authentication (such as fingerprint or facial recognition), and multi-factor authentication (MFA).

Digital payment systems are deeply integrated with e-commerce platforms and mobile applications, facilitating a seamless checkout experience for consumers. Many digital payment providers offer APIs and SDKs that allow businesses to easily integrate payment options into their websites, apps, and online stores.

The digital payment market has expanded its reach to support cross-border transactions, enabling businesses and consumers to send and receive payments internationally with ease. Digital payment platforms often offer currency conversion services and competitive exchange rates, making it easier to conduct business globally.

Major Highlights of the Digital Payment Market

The digital payment market has experienced explosive growth over the past decade, fueled by the increasing adoption of smartphones, internet connectivity, and e-commerce. The convenience, speed, and security of digital payments have led to widespread consumer adoption, with more people using digital wallets, mobile payment apps, and online banking than ever before.

Mobile payments have become a dominant force in the digital payment market, driven by the proliferation of smartphones and the convenience of mobile apps. Platforms like Apple Pay, Google Pay, and Samsung Pay, along with regional players like Alipay and WeChat Pay in China, have revolutionized how people pay for goods and services.

Digital currencies, including cryptocurrencies like Bitcoin, Ethereum, and central bank digital currencies (CBDCs), are gaining traction in the digital payment market. Blockchain technology, which underpins many digital currencies, offers secure and transparent transaction processing, attracting interest from both consumers and businesses.

The COVID-19 pandemic has significantly accelerated the adoption of digital payments. As consumers and businesses sought to minimize physical contact and maintain social distancing, there was a surge in the use of contactless payments, online shopping, and digital wallets.

Governments and regulatory bodies around the world are increasingly supporting the adoption of digital payments through policies, initiatives, and frameworks aimed at promoting a cashless society. In many countries, governments are working to enhance the digital payment infrastructure, improve financial inclusion, and ensure the security and privacy of digital transactions.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=209834053  

Top Companies in the Digital Payment Market

The digital payment market comprises major providers, such as PayPal (US), Fiserv (US), FIS (US), Global Payments (US), Square (US), Stripe (US), VISA (US), Mastercard (US), Worldline (France), Adyen (Netherlands), ACI Worldwide (US), Temenos (Switzerland), PayU (Netherlands), Apple (US), JPMorgan Chase  (US), WEX (US), FLEETCOR (US), Aurus (US), PayTrace (US), Stax by FattMerchant (US), Verifone(US), Spreedly (US), Dwolla (US), BharatPe (India), Payset (UK), PaySend (UK), MatchMove (Singapore), Ripple (US), and EBANX (Brazil). To increase their market share in the Digital payment industry, these competitors have used a variety of growth methods, including partnerships, agreements, collaborations, new product releases, product enhancements, and acquisitions.

PayPal:

PayPal is a leading technology platform and digital payments company. It enables digital and mobile payments on behalf of consumers and merchants across the globe. In April 2023, the new version of PayPal Payment Solution provided acceptance of PayPal payments with Apple Pay, save payment methods with PayPal Vault, and real-time account updater. In October 2021, PayPal launched Zettle Terminal, a new, all-in-one point-of-sale solution that offered increased mobility in-store for small businesses. The Zettle Terminal will be available in the UK beginning today and will continue to roll out across additional markets in Europe in 2021 and into 2022 and the US next year.

Fiserv:

Fiserv is a financial technology and solutions company. The company offers financial services to clients across various industries. The company operates through three business segments: Merchant Acceptance, Financial Technology (Fintech), and Payments. The Payments segment includes products and services required to process digital payment transactions, including card transactions such as debit, credit, and prepaid card processing and services, a range of network services, security and fraud protection products, and card production and print services for financial institutions and corporate clients. In March 2023, Fiserv launched version V11.0 of Banking Hub, bringing about a new API in the Indirect Liability service. In November 2021, Fiserv introduced Clover Online Ordering with Delivery, which provided flexible food delivery services with direct menu management, order and payment processing, and reporting through the Clover platform.

FIS (US)

FIS offers a wide range of financial services and digital payment solutions, including payment processing, banking software, and e-commerce solutions. Their Worldpay division provides comprehensive payment processing services for merchants globally, supporting a variety of payment methods and currencies.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/digital-payment-market-209834053.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Digital Payment Market Recent Growth Factors, Size, Share, Top Companies, Industry Analysis, Future Development & Forecast – 2028

Psychiatric Digital Biomarkers Market 2024: Key Trends, Innovations, and Market Outlook

“Psychiatric Digital Biomarkers Market”
Psychiatric Digital Biomarkers Market is estimated to reach over USD 2,879.7 Mn by 2031, exhibiting a CAGR of 24.7% during the forecast period.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Psychiatric Digital Biomarkers Market”-, By Type (Wearable, Mobile based Applications, Sensors) Clinical Practice (Diagnostic Psychiatric Digital Biomarkers, Monitoring Psychiatric Digital Biomarkers, Predictive and Prognostic Psychiatric Digital Biomarkers), End Use (Healthcare companies, Healthcare Providers, Payers), Industry Trends, and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031.”

The Psychiatric Digital Biomarkers Market is estimated to reach over USD 2,879.7 Mn by 2031, exhibiting a CAGR of 24.7% during the forecast period. 

Psychiatric digital biomarkers are created by measuring physiological and behavioral data gathered through digital devices such as wearables, smartphones, and other digital platforms, which provide objective and quantitative assessments. These biomarkers enable the evaluation, tracking, and prediction of mental health disorders. Advanced algorithms and machine learning techniques analyze the collected data to identify patterns associated with various mental health conditions. For example, machine learning-based voice analysis is used to derive digital biomarkers of cognitive functioning in trauma survivors, while dynamic tracking of changes in biomarkers helps in monitoring Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, depression, and schizophrenia. Additionally, touch screens, keyboards, and microphones serve as biomarkers for motor control and speech in Alzheimer’s patients, respectively, facilitating a comprehensive approach to understanding and managing mental health conditions.

In March 2022, DTU Health Tech researchers created a technique that uses voice analysis to detect mood swings in patients and diagnose bipolar disorder in individuals, with customized models yielding the most accurate findings.

Get Free Access to Demo Report, Excel Pivot and ToC : https://www.insightaceanalytic.com/request-sample/2637

List of Prominent Players in the Psychiatric Digital Biomarkers Market:

  • Koneksa
  • Biogen Inc.
  • BioSensics
  • Empatica Inc.
  • Vivo Sense
  • IXICO plc
  • Huma
  • kintsugi health
  • Sonde Health, Inc.
  • Clario
  • icometrix
  • iMediSync

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Market Dynamics:

Drivers

The rising rates of mental health conditions, such as depression, anxiety, and bipolar disorder, drive the demand for innovative diagnostic and monitoring solutions to manage these disorders effectively. Innovations in wearable technology, mobile applications, sensors, and data analytics have expanded the capabilities of digital biomarkers, making them more accessible and effective for mental health monitoring and management. Increased awareness of mental health issues and the benefits of digital health technologies has led to greater acceptance among patients and healthcare providers, boosting the adoption of digital biomarkers.

Challenges:

Ensuring the protection of sensitive mental health data is crucial. Compliance with data protection regulations, such as GDPR and HIPAA, is required to maintain patient trust and safeguard information from breaches is a significant challenge.

Regional Trends:

North America has the largest market share during the forecast period. The region benefits from well-established regulatory pathways, which facilitate the approval and adoption of new digital health technologies. The widespread use of telehealth and digital health solutions supports the growth of psychiatric digital biomarkers. However, The Asia-Pacific region is an emerging market for psychiatric digital biomarkers, with rapid technological advancements and increasing healthcare expenditure.

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/enquiry-before-buying/2637

Recent Developments:

  • In July 2024, have decided to work together on a cutting-edge mental health treatment program. Sonde Health will evaluate users’ mental health daily using its clinically recognized Mental Fitness vocal biomarker technology. In the meantime, the biggest telecom provider in South Korea, KT Corporation, will provide the necessary services and infrastructure to support users in enhancing their mental well-being.
  • In May 2023, iMediSync, Mila announced a collaboration with iMediSync, a company whose goal is to transform mental health with the application of artificial intelligence (AI) and a data-driven methodology. iMediSync is a global digital mental health firm with headquarters in Korea that specializes on near-infrared light emitting diodes (NIR-LED)-based precision digital treatments and brainwave-centered diagnostics for early screening and prediction of various brain illnesses.

Segmentation of Psychiatric Digital Biomarkers Market.

Global Psychiatric Digital Biomarkers Market – By Type

  • Wearable
  • Mobile based Applications
  • Sensors
  • Others

Global Psychiatric Digital Biomarkers Market – Clinical Practice

  • Diagnostic Psychiatric Digital Biomarkers
  • Monitoring Psychiatric Digital Biomarkers
  • Predictive and Prognostic Psychiatric Digital Biomarkers
  • Other’s

Global Psychiatric Digital Biomarkers Market – End Use

  • Healthcare companies
  • Healthcare Providers
  • Payers
  • Others

Global Psychiatric Digital Biomarkers Market – By Region

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Unlock Your GTM Strategy @ https://www.insightaceanalytic.com/customisation/2637

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Media Contact
Company Name: InsightAce Analytic Pvt. Ltd
Contact Person: Diana D’Souza
Email: Send Email
Country: United States
Website: https://www.insightaceanalytic.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psychiatric Digital Biomarkers Market 2024: Key Trends, Innovations, and Market Outlook

Obesity Pipeline Drugs 2024 | Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehrin

DelveInsight’s, “Obesity Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.

 

Discover the latest drugs and treatment options in the Obesity Pipeline. Dive into DelveInsight’s comprehensive report today! @ Obesity Pipeline Outlook

 

Key Takeaways from the Obesity Pipeline Report

  • August 2024:- Palatin Technologies, Inc- A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide With Tirzepatide (GLP-1/GIP) for the Treatment of Obesity. This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).
  • August 2024:- Novo Nordisk A/S- Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity. This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors.
  • DelveInsight’s Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment.
  • The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
  • Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.

 

Stay ahead with the most recent pipeline outlook for Obesity. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Obesity Treatment Drugs

 

Obesity Emerging Drugs

  • Survodutide: Zealand Pharma

Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity.

  • Ecnoglutide: Sciwind Biosciences

Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity.

  • CT-868: Carmot Therapeutics

CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868’s effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity.

  • DD01: D&D Pharmatech

DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD).

 

Explore groundbreaking therapies and clinical trials in the Obesity Pipeline. Access DelveInsight’s detailed report now! @ New Obesity Drugs

 

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Obesity Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Unveil the future of Obesity Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Obesity Market Drivers and Barriers

 

Scope of the Obesity Pipeline Report

  • Coverage- Global
  • Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
  • Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.
  • Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Obesity Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Obesity Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Obesity Overview
  4. Obesity Pipeline Therapeutics
  5. Obesity Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Survodutide: Zealand Pharma
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. CT-868: Carmot Therapeutics
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. DD01: D&D Pharmatech
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. Drug name: Company name
  17. Drug profiles in the detailed report…..
  18. Inactive Obesity Products
  19. Obesity Key Companies
  20. Obesity Key Products
  21. Obesity Unmet Needs
  22. Obesity Market Drivers
  23. Obesity Market Barriers
  24. Obesity Future Perspectives and Conclusion
  25. Obesity Analyst Views
  26. Obesity Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Pipeline Drugs 2024 | Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehrin

Hemato Oncology Testing Market worth $5.6 billion by 2027

“North America dominated hemato oncology testing market. The largest share can be attributed to the significant advances have been made in cancer treatment driven by advances in personalized medicine, increasing co-development projects, and increasing collaborations for developing new assay tests.”
Browse 97 market data Tables and 32 Figures spread through 145 Pages and in-depth TOC on “Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User – Global Forecast to 2027

Hemato Oncology Testing Market is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 Billion in 2022, at a CAGR of 14.2% according to a new report by MarketsandMarkets™. The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877

The Services segment accounted for the largest share of the Hemato oncology testing devices market, by product type, in 2021

On the basis of products & services type, the global hemato oncology testing market is segmented into services and assay kits. The services segment accounted for the largest share of the global hemato oncology testing market in 2021. This can be attributed to the high and growing prevalence of leukemia and lymphoma.

The segment accounted for the largest share of the Hemato oncology testing devices market, by cancer type, in 2021

By cancer type, the global leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market.  This can be attributed to factor such as the increasing prevalence and incidence of lymphoma is a major driving factor for this market.

PCR segment is anticipated to hold major share of the global Hemato oncology testing market in 2021

By technology, the global hemato oncology testing market is broadly segmented into PCR, IHC, NGS, cytogenetics, and other technologies. In 2021, the PCR segment dominated hemato oncology testing market. Factors supporting the growth of the segment is  the wide use of this technology owing to its ease of use and easy availability of assay kits.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877

North America to hold a significant share of the Hemato oncology testing market during the forecast period in 2021

The global hemato oncology testing market is segmented into North America, Europe, Asia Pacific, and ROW. North America dominated hemato oncology testing market. The largest share can be attributed to the significant advances have been made in cancer treatment driven by advances in personalized medicine, increasing co-development projects, and increasing collaborations for developing new assay tests.

The major players operating in the Hemato oncology testing market Abbott Laboratories (US), F. Hoffman-La Roche (Switzerland), QIAGEN (Germany), Thermo Fisher Scientific (US), Illumina (US), Bio-Rad Laboratories (US), MolecularMD (Ireland), ArcherDX (US), ARUP Laboratories (US), Asuragen (US), Invivoscribe (US), Adaptive Biotechnologies (US), Amoy Diagnostics (China), ELITechGroup (France), Vela Diagnostics (Singapore), Gentronix (UK), BioIVT (US), SAGA Diagnostics (Sweden), Olink (Sweden) and Cancer Diagnostics (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=262472877

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.prnewswire.com/news-releases/hemato-oncology-testing-market-worth-5-6-billion-by-2027—exclusive-report-by-marketsandmarkets-301685926.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemato Oncology Testing Market worth $5.6 billion by 2027

Gracias Living Revolutionizes Senior Care with Groundbreaking Dementia Care Programs

Gracias Living Revolutionizes Senior Care with Groundbreaking Dementia Care Programs

Gracias Living is turning heads with its Caring approach to Senior and Assisted Living with dementia care, setting new benchmarks in the industry. The Gurgaon-based facility is garnering widespread attention for its innovative programs designed to enhance the quality of life for its residents.

Pioneering Assisted Living Services

Gracias Living is redefining assisted living with its comprehensive and personalized care solutions. The facility offers:

  • Tailored Assistance: Customized support plans that address individual needs, from daily activities to medical care, ensuring each resident’s unique requirements are precisely met.
  • Engaging Social Programs: Various social and recreational activities are designed to promote interaction and community, enhancing residents’ emotional and mental well-being.
  • Wellness and Health: A focus on holistic wellness, including access to on-site physiotherapy, nutritional guidance, and health monitoring to support overall health and vitality.

These initiatives reflect Gracias Living’s commitment to providing high-quality, personalized care that supports independence while ensuring safety and comfort.

Dementia Care Breakthroughs

Expanding on its assisted living services, Gracias Living has introduced groundbreaking programs specifically tailored for individuals with dementia. These include:

  • Advanced Memory Activities: Puzzles and memory-enhancing exercises designed to boost cognitive function.
  • Sensory Stimulation Techniques: State-of-the-art sensory therapies, including aromatherapy and music therapy, aimed at calming and engaging residents.
  • Creative Therapies: Innovative art and music therapy sessions that offer new avenues for emotional expression and mental stimulation.

These dementia-focused programs are capturing the interest of the caregiving community and setting a new standard in dementia care.

Family Support and Education

In addition to its dementia programs, Gracias Living is acclaimed for its comprehensive support for families. The facility offers specialized workshops and support groups to educate and empower caregivers, providing them with valuable tools and resources.

Enhanced Safety and Community Focus

Gracias Living’s commitment to safety and community is evident in its thoughtfully designed living spaces. The facility features secure, navigable environments with clear signage and structured daily routines, ensuring both comfort and security for its residents.

Industry Impact

The innovative practices and community-focused approach of Gracias Living are causing a stir in the senior care industry. The facility’s efforts are being recognized for their potential to transform dementia care and improve the overall quality of life for seniors.

About Gracias Living

Gracias Living is a leading senior and assisted living community in Gurgaon, dedicated to providing exceptional care and innovative solutions for its residents. For more information, visit https://graciasliving.com

Media Contact
Company Name: Gracias Living
Email: Send Email
City: Gurgaon
Country: India
Website: https://graciasliving.com/

Stéphane Bellucci Featured in Online Interview on Bmmagazine

Stéphane Bellucci Featured in Online Interview on Bmmagazine

Stéphane Bellucci, Montreal, QC, Canada

Stéphane Bellucci, President of Bellucci Ltd and a leader in the specialty coffee machine industry, has been featured in an exclusive interview with Bmmagazine, where he shares insights into his journey, the values that drive his business, and his vision for the future of the coffee industry.

In this in-depth interview, Stéphane Bellucci discusses the origins of Bellucci Ltd and how his experiences, both personal and professional, have shaped the company’s success. From his early days as a competitive swimmer in Montreal to his tenure as General Manager at Saeco Canada, Bellucci’s story is one of perseverance, innovation, and a relentless commitment to excellence.

The interview explores key aspects of Bellucci Ltd’s strategy, including the importance of innovation in staying ahead in the competitive specialty coffee machine market. Stéphane emphasizes how technological advancements and a deep understanding of customer needs have allowed Bellucci Ltd to sell and create products that resonate with true coffee enthusiasts. He also touches on the significance of balancing professional responsibilities with personal passions, such as aviation, and how this balance contributes to his success as a business leader.

Stéphane Bellucci also provides valuable advice for entrepreneurs looking to succeed in niche markets, stressing the importance of specialization, customer loyalty, and continuous innovation. He discusses the future of Bellucci Ltd in the evolving coffee industry, highlighting the company’s commitment to sustainability and its plans for expansion.

Philanthropy is another important theme in the interview. Stéphane shares how his philanthropic efforts, including supporting the Canadian Red Cross and breakfast programs for underprivileged students, align with his business values. He believes that giving back is not just about charity but about building a legacy of compassion and responsibility that complements the success of Bellucci Ltd.

About Stéphane Bellucci

Stéphane Bellucci is the President of Bellucci Ltd, a leading supplier and manufacturer of specialty espresso machines in Canada. With a career spanning decades, Stéphane has established himself as a pioneer in the coffee industry through his dedication to quality, innovation, and customer satisfaction. His journey began in Montreal , where he developed a strong work ethic as a competitive swimmer. After serving as General Manager for Saeco Canada, Stéphane founded Bellucci Ltd with his brother, where he continues to lead the company to new heights. Beyond his professional achievements, Stéphane is an aviation enthusiast and philanthropist, regularly contributing to causes close to his heart, such as the Canadian Red Cross and breakfast programs for underprivileged students.

To read the full interview, click here.

Media Contact
Contact Person: Stéphane Bellucci
Email: Send Email
City: Montreal
State: QC
Country: Canada
Website: https://www.stephanebellucci.com/

Stéphane Bellucci Featured in Exclusive Interview on IdeaMensch

Stéphane Bellucci Featured in Exclusive Interview on IdeaMensch

Stéphane Bellucci, Montreal, QC, Canada
Stéphane Bellucci, President of Bellucci Ltd and a prominent leader in the specialty coffee machine industry, has been featured in an exclusive interview on IdeaMensch.

Stéphane Bellucci, President of Bellucci Ltd and a prominent leader in the specialty coffee machine industry, has been featured in an exclusive interview on IdeaMensch. In this insightful discussion, Stéphane shares his perspectives on leadership, innovation, and the strategies that have driven Bellucci Ltd to success.

In the interview, Stéphane Bellucci offers a glimpse into his daily routine, highlighting the importance of a structured morning to kickstart productivity. He delves into the processes that bring ideas to life at Bellucci Ltd, emphasizing the role of innovation and collaboration in creating cutting-edge espresso machines. Stéphane also discusses current trends that excite him, particularly the growing demand for sustainable products, and how Bellucci Ltd is responding to this shift with eco-friendly innovations.

The interview provides valuable advice for entrepreneurs, with Stéphane reflecting on the importance of trusting the process, embracing calculated risks, and focusing on quality over quantity. He also shares his belief in the power of listening to customers, a practice that has been instrumental in Bellucci Ltd’s customer-centric approach.

Stéphane candidly discusses a past failure in his career, offering insights into how he overcame it and the lessons learned about market research and timing. He also introduces a business idea centered around eco-friendly, compostable coffee pods — a concept aligned with his commitment to sustainability.

This interview is a must-read for anyone interested in entrepreneurship, innovation, and the specialty coffee industry.

About Stéphane Bellucci

Stéphane Bellucci is the President of Bellucci Ltd, a leading supplier and manufacturer of specialty espresso machines in Canada. With a career spanning decades, Stéphane has established himself as a pioneer in the coffee industry through his dedication to quality, innovation, and customer satisfaction. Born and raised in Montreal , where he developed a strong work ethic as a competitive swimmer, Stéphane later served as General Manager for Saeco Canada before founding Bellucci Ltd. Beyond his professional accomplishments, Stéphane is an aviation enthusiast and philanthropist, regularly contributing to causes close to his heart, such as the Canadian Red Cross and breakfast programs for underprivileged students.

To read the full interview, click here.

Media Contact
Contact Person: Stéphane Bellucci
Email: Send Email
City: Montreal
State: QC
Country: Canada
Website: https://www.stephanebellucci.com/

Axillary Hyperhidrosis Pipeline Drugs 2024 | GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical

DelveInsight’s, “Axillary Hyperhidrosis Pipeline Insight 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Axillary Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Axillary Hyperhidrosis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Axillary Hyperhidrosis Pipeline Outlook

 

Key Takeaways from the Axillary Hyperhidrosis Pipeline Report

  • January 2024:- InMode MD Ltd.- The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF. The Morpheus8 Applicator and 24 pin tip is used for the treatment of primary hyperhidrosis of the axillae.
  • DelveInsight’s Axillary Hyperhidrosis pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Axillary Hyperhidrosis treatment.
  • The leading Axillary Hyperhidrosis Companies such as GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical, and others.
  • Promising Axillary Hyperhidrosis Therapies such as Sofpironium bromide, ET-01, DMT410, and others.

 

Stay ahead with the most recent pipeline outlook for Axillary Hyperhidrosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Axillary Hyperhidrosis Treatment Drugs

 

Axillary Hyperhidrosis Emerging Drugs

  • Sofpironium bromide: Brickell Biotech Inc.

Sofpironium bromide is a new chemical entity that we are currently developing in the U.S. as a potential best-in-class, self-administered, once-daily, topical therapy for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating. The drug is a retro metabolically designed anticholinergic agent which selectively binds to M3 AC receptor potentially inhibiting sweat production.

  • ET-01: Eirion Therapeutics

ET-01 is a topical botulinum product being developed with the goal of avoiding the pain, bleeding and bruising that can be associated with the injection of commercially available botulinum products. ET-01 employs a nanoemulsion transdermal delivery technology essential for a large molecule such as botulinum to penetrate into the skin.The drug is currently being developed in Phase 2 stage of development for the treatment of Axillary Hyperhidrosis.

  • DMT410: Dermata Therapeutics LLC pipeline

DMT410 is the second development program using DMT400 combination regimen in combination with botulinum toxin. Dermata Therapeutics have completed a proof of concept, Phase 1 clinical trial using DMT410 in combination with BOTOX® for the treatment of primary axillary hyperhidrosis. The treatment was well tolerated, and a majority of patients saw a reduction in sweat production similar to results seen from using injections of BOTOX®.

 

Explore groundbreaking therapies and clinical trials in the Axillary Hyperhidrosis Pipeline. Access DelveInsight’s detailed report now! @ New Axillary Hyperhidrosis Drugs

 

Axillary Hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Axillary Hyperhidrosis Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Unveil the future of Axillary Hyperhidrosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Axillary Hyperhidrosis Market Drivers and Barriers

 

Scope of the Axillary Hyperhidrosis Pipeline Report

  • Coverage- Global
  • Axillary Hyperhidrosis Companies- GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical, and others.
  • Axillary Hyperhidrosis Therapies- Sofpironium bromide, ET-01, DMT410, and others.
  • Axillary Hyperhidrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Axillary Hyperhidrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Axillary Hyperhidrosis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Axillary Hyperhidrosis Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Axillary Hyperhidrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Axillary Hyperhidrosis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Sofpironium bromide: Brickell Biotech Inc
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. Drug Name: Company Name
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. ET-01: Eirion Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Axillary Hyperhidrosis Key Companies
  21. Axillary Hyperhidrosis Key Products
  22. Axillary Hyperhidrosis – Unmet Needs
  23. Axillary Hyperhidrosis – Market Drivers and Barriers
  24. Axillary Hyperhidrosis – Future Perspectives and Conclusion
  25. Axillary Hyperhidrosis Analyst Views
  26. Axillary Hyperhidrosis Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Axillary Hyperhidrosis Pipeline Drugs 2024 | GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical